NEW APPROACHES TO THERAPY OF RHEUMATOID-A RTHRITIS (RA)

Design of highly selective biological substances made use of three bas ic components of a complex pathogenetic model of RA: the presence of a ntigen-presenting cells, genetic defects and autoimmune aggression. Ef forts now are directed to development of monoclonal antibodies (MAB) t o receptors of T-cells, B lymphocytes, MAB to CD 18 and CD54, cytokine s, search for natural inhibitors of cytokines, introduction of cytokin es. Many of such preparations including recombinant interferons proved clinically promising.